logo
logo

Freenome Raises $300M In Series D Financing To Advance Multiomics Platform For Early Cancer Detection

Dec 07, 2021over 3 years ago

Amount Raised

$300 Million

Round Type

series d

San FranciscoBiotechnologyScience And EngineeringHealth Care

Description

Freenome, a privately held biotech company, today announced a Series D funding of $300 million. This brings the company's total financing to over $800 million since the company was founded in 2014.

Company Information

Company

Freenome

Location

San Francisco, California, United States

About

Freenome is a biotechnology company with a comprehensive multiomics platform for early cancer detection using a routine blood draw. The company combines its deep expertise in molecular biology with advanced computational biology and machine learning to detect disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is headquartered in South San Francisco, California. 1 Joseph DA, King JB, Dowling NF, Thomas CC, Richardson LC. Vital Signs: Colorectal Cancer Screening Test Use — United States, 2018. MMWR Morb Mortal Wkly Rep 2020;69:253–259. 2 United States Preventive Services Task Force (USPSTF), "Colorectal Cancer: Screening", May 18, 2021. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening SOURCE Freenome Holdings, Inc.

Related People

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech